DLI is traditionally used to provide graft-versus-leukemia (GvL) effects when given to patients relapsing post-hematopoietic cell transplantation (HCT). However, it is often associated with significant GvHD and has only modest efficacy against acute leukemias. Therefore, novel cellular therapies are needed to improve the outcome of high-risk or relapsed leukemia patients following HCT. Activated T helper-1 (aTh-1) lymphocytes are CD4 + CD25 + CD40L + CD62L lo effector memory cells that produce large amounts of IFN-γ and TNF-α. We demonstrate that post-transplant adoptive aTh-1 cell therapy enhances GvL with limited GvHD in an MHC-mismatched murine BMT model. aTh-1 infusions result in superior leukemia-free survival when compared with unstimulated splenocytes (SC), purified CD4 + T-cells and T-cell-enriched SC. aTh-1 cells display cytotoxicity against A20 leukemia cells in vitro and persist in vivo for at least 2 months following adoptive transfer. Furthermore, in contrast to unstimulated SC, aTh-1 cell infusion is associated with only transient, mild suppression of donor-derived hematopoiesis. aTh-1 cell therapy is safe, effective and warrants further investigation as an alternative to DLI.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) offers patients with high-risk leukemias the prospect of curative therapy. It is well documented that patients who develop acute and/or chronic GvHD have lower relapse rates because of concurrent GvL. [1] [2] [3] [4] Various strategies have been utilized to prevent or alleviate GvHD with the hope of preserving GvL. Many of these approaches have significant limitations. In vivo donor T-cell depletion using antithymocyte globulin or alemtuzumab reduces the severity of GvHD but leads to delayed immune reconstitution, higher incidence of infection and higher relapse rates. 5, 6 Selective depletion of anti-host alloreactive T-cells by anti-CD25 immunotoxin, magnetic beads or photodynamic purging accelerates posttransplant T-cell reconstitution and reduces infection-related mortality but leads to insufficient GvL. [7] [8] [9] Ex vivo exposure of donor lymphocytes to Fas ligand preferentially depletes CD62L + and CD69 + T-cell subsets, suppressing GvHD without impairing hematopoietic cell engraftment. However, GvL is not enhanced by this approach. 10 More recently, CD19-specific chimeric antigen receptor donor-derived allogeneic T-cells were given post allogeneic BMT. None of the 10 patients developed GvHD after receiving chimeric antigen receptor-modified donor T-cells. However, objective responses were only seen in three patients. 11 Therefore, effective cellular therapies are needed that can be optimized to induce GvL with an acceptable degree of GvHD.
DLI is used to provide GvL effects to patients relapsing post-HCT. Although DLI has been effective in achieving remissions in chronic myelogenous leukemia relapsing following HCT, it has been much less effective against acute leukemias.
12, 13 Moreover, a significant proportion of patients who receive DLI develop GvHD, which in many cases can be life-threatening. 14 The purpose of the current study was to test, in an allogeneic MHC-mismatched murine BMT setting, the potential of activated allogeneic T helper-1 (aTh-1) lymphocytes to induce GvL while evaluating GvHD. Fully MHC-mismatched HCTs are not performed clinically. However, this model allowed us to study the full GvHD potential of aTh-1 cells. Herein, we demonstrate that aTh-1 cell therapy enhances GvL with minimal GvHD in mice with aggressive lymphoblastic leukemia, resulting in superior leukemia-free survival compared with unstimulated splenocyte infusion.
MATERIALS AND METHODS Mice
Age-matched 4-10-week-old female BALB/c (CD45 
Cell culture
Unless otherwise specified, cells were cultured in complete RPMI medium, which is RPMI 1640 Media with L-glutamine (Thermo-Scientific, Hudson, NH, USA), 10% heat-inactivated FBS (Thermo-Scientific), 1% 100 mM sodium pyruvate (Thermo-Scientific), 1% Minimum Essential Medium Nonessential Amino Acids (Mediatech, Manassas, VA, USA) and 1% penicillin-streptomycin (Gibco, Grand Island, NY, USA) at 37°C and 5% CO 2 .
aTh-1 cell generation CD4 + cells were isolated from the spleens by positive selection using CD4 (L3T4) MicroBeads (Miltenyi Biotec, Auburn, CA, USA) with >90% purity.
CD4
+ cells were cultured with anti-CD3 and anti-CD28 paramagnetic activation beads (Dynabeads Mouse T-activator CD3/CD28 for T-cell Expansion and Activation; Gibco) at a 3:1 bead-to-cell ratio in the presence of murine IL-12 (10 ng/mL), IL-7 (20 ng/mL), IL-2 (20 IU/mL; Peprotech, Rocky Hill, NJ, USA) and anti-IL-4 antibody (5 μg/mL; eBioscience, San Diego, CA, USA). 15 On day 3, cells were harvested, activation beads were removed and the cells were re-stimulated at a 1:1 bead-to-cell ratio in the presence of 20 IU/mL of IL-2 for 4 h before use. For in vitro phenotyping of aTh-1 cells, cells were cultured for 5 days. Fresh medium, activation beads and cytokines were added on day 3. Cells were cultured in complete RPMI medium with 0.1% 55 mM betamercaptoethanol (Gibco).
Preparation of CD4
+ T-cells and T-cell-enriched splenocytes CD4 + T-cells were isolated from spleens by negative selection using mouse CD4 + T-Cell Isolation Kit II (Miltenyi Biotec) with a purity of >90%. T-cellenriched splenocytes (SC), which consisted of >65% CD8 + and CD4 + T-cells, were obtained using nylon wool fiber columns (Polysciences, Inc., Warrington, PA, USA).
Flow cytometry
Cells were incubated with anti-mouse CD16/CD32 (eBioscience) for 15 min, followed by incubation with fluorochrome-conjugated antibodies for 30 min. For intracellular staining, cells were fixed and permeabilized (Transcription Factor Fixation/Permeabilization; eBioscience) and stained with the indicated antibodies. Cells were analyzed using an LSR Fortessa cell analyzer (BD Biosciences, San Jose, CA, USA). Data were analyzed using FlowJo 2 (Tree Star, Ashland, OR, USA). Antibodies used were anti-mouse IFN-γ PE, CD40L APC, CD69 PE, Tbet PE, CD44 PE-Cy7, CD25 APC, CD62L FITC, CD45RB FITC, CD4 APC, CD45.1 APC, CD45.2 APC-eFluor780, CD8a PECy7, Ki-67 eFluor450, Gr-1 FITC, CD11b eFluor450 (eBioscience), B220 BV510, CD4 PE-Cy5 (BioLegend, San Diego, CA, USA) and CD3ε PE-CF594 (BD Biosciences).
Enzyme-linked immuosorbent assay aTh-1 cells were cultured for 5 days. On each day, cells were harvested, de-beaded and re-stimulated for 4 h with IL-2 and activation beads. The supernatant was collected, and the amounts of IFN-γ, TNF-α and GM-CSF were determined by using enzyme-linked immunosorbent assay (ELISA) kits following the manufacturer's protocol (eBioscience).
Tumor cell line
The A20 cell line, a B-cell lymphoblastic leukemia cell line of BALB/c origin, was obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in complete RPMI medium. A20 cells are radioresistant and have been previously used in murine BMT studies. T-cell-enriched SC, or 10 7 total SC. Moribund mice were euthanized, and survival was monitored. The lowest weight each mouse achieved, as a percentage of the last weight before adoptive cell transfer, was determined. Mice were considered cured after day 100 if no tumor was found during necropsy. Histological analysis was used to confirm lack of tumor cells in the liver.
Histology
Mice were euthanized 5 days after adoptive cell transfer. Liver, distal colon and proximal colon were collected and fixed in 10% formalin (Fisher Scientific, Waltham, MA, USA). Hematoxylin and eosin staining was done at the University of Arizona's University Animal Care Pathology Services Laboratory and blindly scored by a veterinary pathologist. Proximal and distal colons were scored separately for mucosal proliferation and inflammation and extent of dysplasia as previously described, 17 and the sum was considered the score for the entire colon.
In vivo tracking of adoptively transferred lymphocytes ) on day +12. On days +3, 7, 10, 17, 24 and 31 after adoptive cell transfer, peripheral blood was collected from recipient mice by tail vein bleeding. Complete blood counts were obtained using a Coulter AcT counter (Beckman Coulter, Brea, CA, USA). The presence and phenotype of adoptively transferred aTh-1 cells and SC, as well as lineage differentiation of engrafted donor BM cells, were determined by flow cytometry. On day 66, the persistence of the adoptively transferred cell populations was confirmed, but lineage differentiation was not examined. Ki-67 staining was done on days 4, 8, 11, 18 and 25. Absolute numbers of individual cell populations were calculated using the total white blood cell count and percentage of cells positive for the indicated markers.
Cytotoxicity assay
Chromium-release ( 51 Cr) assays were performed using C57BL/6 SC and aTh-1 cells as effectors and A20 cells as targets. Cytotoxicity was determined as previously described. 18 Statistics Kaplan-Meier curves were generated and analyzed by the log-rank test to determine survival percentages and differences between the treatment groups. In other experiments, Student's t-tests were used to determine significant differences (Po 0.05) between groups. Unless otherwise specified, all experiments were reproduced at least three times, and data are expressed as mean ± s.e.m. 19 We were, however, concerned that with prolonged culture, aTh-1 may undergo activation-induced cell death shortly after their infusion, thus limiting their in vivo activity. We therefore evaluated cytokine production kinetics and surface marker and transcription factor expression of cultured aTh-1 cells serially over 5 days. We found that the production of IFN-γ and TNF-α peaks on day 4 of culture, while GM-CSF is highest on day 5 (Figure 1a) . Expression of CD44, CD69, CD40L and Tbet is consistent with aTh-1 cells that evolve into an effector memory phenotype (CD62L lo CD45RB hi CD44 hi Tbet + ). These cells do not express markers for regulatory T-cells, such as FoxP3 (Figure 1b) . Collectively, these data suggest that infusion of day 3 aTh-1 cells may have the advantage of producing more cytokines in vivo, without significant differences in the expression of most surface markers and transcription factors examined. In addition, reducing the in vitro culture time by 50% makes these cells more appealing for potential clinical application.
aTh-1 cell infusion is associated with significantly reduced GvHD compared with unstimulated SC, CD4 + T-cells or T-cell-enriched SC It is technically challenging to isolate large numbers of peripheral blood lymphocytes from mice. Therefore, SC, which have the same CD4 to CD8 T lymphocyte ratio as murine blood, were used as comparable to human DLI. Because aTh-1 cells are activated effector memory CD4 + T-cells, as additional treatment controls, we used unstimulated purified splenic CD4
+ T-cells and T-cellenriched SC. To evaluate whether aTh-1 cell therapy induces GvHD, BALB/c mice were infused with 3 × 10 6 C57BL/6 aTh-1 cells on days +12 and +17 following MHC-mismatched TCD BMT. Other groups received 10 7 SC, containing approximately 3 × 10 6 T-cells (data not shown), 3 × 10 6 CD4 + T-cells or 3 × 10 6 T-cell-enriched SC. Reproducibly, >80% of SC-treated mice died of GvHD. In contrast, GvHD was the cause of death in o20% of the mice receiving aTh-1 cells (Figure 2a Images at × 50 magnification. *P o0.05, ***P o0.001.
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T-cells or T-cell-enriched SC exhibited significant weight loss when compared with mice receiving aTh-1 cells (Figure 2b ). Colons from mice treated with SC showed subacute multifocal coalescing colitis with crypt hyperplasia and mixed lymphocytic and neutrophilic infiltrates, consistent with GvHD (Figure 2c, i) . Histological colon GvHD scores of mice receiving aTh-1 cells were comparable to those of mice receiving BMT alone (Figure 2c , ii). Like total SC, both CD4 + T-cells and T-cell-enriched SC induced significant colonic GvHD (Figure 2c, iii) . Mice receiving aTh-1 showed no significant abnormality in their livers. In comparison, PBS-treated mice receiving A20 showed hepatic leukemic infiltration, indicating inadequate GvL effects provided by TCD BMT alone. Mice receiving SC, while showing no leukemic infiltration, developed multifocal chronic active cholangitis, indicating liver GvHD (Figure 2d) . We further evaluated the GvHD resulting from different doses (1 × 10 6 and 3 × 10 6 ) of aTh-1 cells, CD4
+ T-cells and T-cell-enriched SC and found that CD4 + T-cells and T-cell-enriched SC led to 100% death from GvHD at both doses. We saw no difference in GvHD from aTh-1 cells (Supplementary Figure S1) . Together, our data demonstrate that aTh-1 therapy is associated with significantly lower GvHD mortality and morbidity when compared with total SC, unstimulated purified CD4 + T-cells and T-cell-enriched SC.
aTh-1 cell infusion following MHC-mismatched BMT improves leukemia-free survival in mice MHC-mismatched allogeneic aTh-1 cells have been previously reported to induce anti-leukemic effects in non-transplant murine settings. 15, 20 Given that aTh-1 cells induced significantly less GvHD than SC, we used the same model to evaluate whether aTh-1 cell therapy was capable of promoting GvL effects. Without BMT, 100% of the mice died from leukemia. TBI, followed by BMT, although significantly prolonging survival, failed to cure any mice (Figure 3) . Although SC effectively abated leukemia, as confirmed by the absence of leukemia in the livers (Figure 2d) , survival was not improved as >80% of mice died of GvHD (Figure 2a) . aTh-1 cell infusion (3 × 10 6 ) led to leukemia-free survival in 50% of mice ( Figure 3) . The absence of leukemia in the surviving mice 100 days post-BMT was confirmed by histology (data not shown). We found no difference in leukemia-free survival when mice were treated with 1 × 10 6 aTh-1 cells (data not shown). In summary, aTh-1 cells cause minimal GvHD in a fully MHC-mismatched BMT model and retain significant anti-leukemic properties. + proliferative SC was significantly higher than that of aTh-1 cells (Figure 4a ). On day 7 following adoptive transfer of equal numbers of CD45.1 + aTh-1 and SC, the absolute number of peripheral blood CD45.1 + SC was sixfold greater than that of aTh-1 cells. On day 10, this difference was >10-fold (Figure 4b ). The expansion of the SC in vivo preceded the development of clinical signs of GvHD, including significant weight loss, diarrhea, hunched posture, lethargy, ruffled fur, alopecia and tachypnea. (Figure 5a ). This observation indicates persistent suppression of donor hematopoietic reconstitution by SC. In contrast, aTh-1 cell infusion resulted in transient, mild suppression of donor hematopoiesis (Figure 5a) . Furthermore, SC infusion resulted in skewed immune reconstitution, including an increased percentage of myeloid cells, particularly PMNs, a decreased percentage of B-cells (Figure 5b) and a decreased or inverted CD4 to CD8 T-cell ratio (Supplementary Figure S2) . The increase in monocytes was lower and transient in aTh-1 cell-treated mice, with no significant differences in the percentages of PMNs, B-cells, T-cells (Figure 5b) or the CD4 to CD8 ratio (Supplementary Figure S2) , when compared with control mice.
aTh-1 cells display direct cytotoxicity against A20 leukemia cells To evaluate whether the anti-leukemic effects elicited by aTh-1 cells are the result of direct cytotoxicity against A20 leukemia cells, chromium release assays were performed. Allogeneic aTh-1 cells displayed direct cytotoxicity against A20 cells in vitro (Supplementary Figure S3) . Supernatant from aTh-1 cell culture failed to lyse A20 cells (data not shown), indicating that cell-to-cell contact is required for the cytolytic activity of aTh-1 cells. As there wereo 2% CD8 + T-cells in the aTh-1 cells at the time of injection (data not shown), the observed cytotoxicity against A20 cells was unlikely a result of allo-reactive CD8 + CTLs.
DISCUSSION
A major challenge in allogeneic HCT is how to dissociate GvL from GvHD. In this study, we demonstrate that adoptive transfer of CD4 + CD25 + CD40L + CD62L lo effector memory aTh-1 cells provides GvL without inducing significant GvHD in MHC-mismatched allogeneic hosts. Our finding is in accordance with observations from others that CD62L
− memory T-cells are inept at inducing GvHD in allogeneic BMT recipients. [22] [23] [24] In contrast to ** 
CD62L
− memory T-cells that are obtained by FACS, our aTh-1 cells are generated from bulk CD4 + T-cells and are used following 3 days of in vitro culture, resulting in a potentially clinically useful higher cell yield.
aTh-1 cells do not express markers for regulatory T-cells such as FoxP3 (Figure 1b) , suggesting that the lack of significant GvHD in vivo is not due to immunosuppressive activity of regulatory T-cells in the adoptively transferred population. Following adoptive transfer, aTh-1 cells proliferated in vivo and persisted for at least 2 months, indicating that activation-induced cell death did not take place post infusion. At the onset of GvHD, a threshold number of effector T-cells may need to infiltrate a given target tissue to initiate sufficient tissue damage to establish local changes that promote recruitment of additional activated T-cells. [24] [25] [26] [27] We have shown that after infusion adoptively transferred SC undergo rapid expansion at a much higher rate than aTh-1 cells, suggesting that GvHD may require a sustained highly proliferative allogeneic T-cell response that SC, but not aTh-1 cells, can generate.
aTh-1 cells differ from effector memory cells reported by others in that they are activated and secrete large amounts of type-1 cytokines and are therefore possibly endowed with an enhanced GvL capacity. Previous murine studies demonstrated that CD4 + effector memory T-cells mediate GvL via direct cytotoxicity against leukemia cells. 24 On the other hand, Zorn et al. 28 reported that CD4 + DLI induces expansion of CD8 + donor CTLs with cytolytic activity against leukemia cells and recipient hematopoietic cells that express mHA. It is noteworthy that the methodology utilized by Zorn et al. 28 did not allow one to distinguish between donor BM-derived CD8 + T-cells and residual CD8 + T-cells in the DLI preparation. In our study, allogeneic aTh-1 cells exhibited direct cytotoxicity against A20 leukemia cells in vitro. Syngeneic aTh-1 cells also displayed some cytotoxicity against A20 cells, although at a much lower level than allogeneic aTh-1 cells (data not shown), indicating that allo-antigen-mediated T-cell response contributed to the overall cytotoxicity but was not the sole factor. Furthermore, given that aTh-1 cells provide adjuvant effects to tumor vaccination, 19 it is possible that other effector cells, such as natural killer cells and macrophages, are activated by aTh-1 cells via type-1 cytokines and mediate GvL in vivo. aTh-1 cells may also enhance GvL by modulating FoxP3 + Treg, thus contributing to breaking tumor tolerance. 19 Hematopoietic stem cell engraftment and reconstitution following HCT are affected by a variety of factors, including graft source, GvHD and host BM microenvironment. The effect of mature donor T-cells on hematopoietic stem cell engraftment and immune recovery has been controversial. Early attempts to reduce GvHD by T-cell depletion were associated with increased risk of graft failure and suppressed immune recovery, [29] [30] [31] [32] indicating that donor T-cells may facilitate engraftment and hematopoietic reconstitution. However, later clinical trials suggested that these results could have been due to insufficient hematopoietic stem/ progenitor content in the manipulated BM. [33] [34] [35] Moreover, murine studies provide evidence that allogeneic T-cells impair hematopoietic reconstitution after HCT. 36, 37 On the other hand, CD62L
− effector memory T-cells have been shown to promote donor BM stem/progenitor-derived T-cell reconstitution. 23 In our study, in contrast to SC, aTh-1 cell therapy induced mild, transient suppression of donor hematopoiesis. Adoptive transfer of SC led to skewed immune reconstitution characterized by severe B lymphopenia, inverted CD4 to CD8 T-cell ratio and predominance of the myeloid fraction in the blood. Our finding is consistent with previous reports that GvHD is associated with lymphoid hypoplasia and impairs immune function post-HCT. 19, 20, 22, [38] [39] [40] Lack of significant GvHD after aTh-1 cell infusion may partially explain why the cells do not have detrimental effects on hematopoiesis following allogeneic BMT.
In summary, utilizing an MHC-mismatched murine BMT model, we demonstrate that aTh-1 cells enhance GvL without inducing significant GvHD following allogeneic HCT. Furthermore, in contrast to SC, aTh-1 cell infusion does not cause severe, persistent suppression of donor-derived hematopoiesis. aTh-1 cell therapy, therefore, may provide an effective alternative to DLI. Although the mHA mismatch models may resemble clinical HLA matched BMT, the MHC-disparate system allows for the full spectrum of clinically relevant GVHD, permitting evaluation of immunological mechanisms of GvHD. 41 Considering that GvHD is more severe in MHC-mismatched HCT than in mHAmismatched HCT, our finding that aTh-1 cellular therapy is associated with minimal GvHD indicates that this approach is safe and effective and should be explored for potential clinical application.
